1. Chest wall reconstruction with implantable cross-linked porcine dermal collagen matrix: Evaluation of clinical outcomes
- Author
-
Alessandro Gonfiotti, Domenico Viggiano, Eduart Vokrri, Marco Lucchi, Duilio Divisi, Roberto Crisci, Felice Mucilli, Federico Venuta, and Luca Voltolini
- Subjects
latissimus dorsi ,polytetrafluoroethylene ,Pulmonary and Respiratory Medicine ,biological mesh ,PM ,PMCWT ,cross-linked porcine dermal collagen matrix ,LD ,secondary chest wall tumor ,CWR, chest wall reconstruction ,LD, latissimus dorsi ,PACLIDEM, porcine-derived acellular cross-linked dermal matrix ,PCWT, primary chest wall tumor ,PM, pectoral major ,PMCWT, primary malignant chest wall tumor ,PTFE, polytetrafluoroethylene ,SCWT, secondary chest wall tumor ,chest wall reconstruction ,chest wall tumor ,titanium bar ,PACLIDEM ,PCWT ,SCWT ,CWR ,primary malignant chest wall tumor ,porcine-derived acellular cross-linked dermal matrix ,primary chest wall tumor ,Surgery ,pectoral major ,PTFE - Abstract
The aim of the study is to evaluate clinical applications, safety, and effectiveness of a porcine-derived acellular cross-linked dermal matrix biological mesh in chest wall reconstruction.We retrospectively analyzed a prospective multicenter database of chest wall reconstructions using a biological mesh in adult patients undergoing operation between October 2013 and December 2020. We evaluated preoperative data, type of resection and reconstruction, hospitalization, 30-day morbidity and mortality, and overall survival.A total of 105 patients (36 women [34.2%]; mean age, 57.0 ± 16.1 years; range, 18-90 years) were included, they have admitted for: primary chest wall tumor (n = 52; 49.5%), secondary chest wall tumor (n = 29; 27.6%), lung hernia (n = 12; 11.4%), trauma (n = 10; 9.6%), and infections (n = 2; 1.9%). The surgical sites were preoperatively defined as at high risk of infection in 28 patients (26.7%) or as infected in 16 (15.2%) patients. Thirty-days morbidity was 30.5% (n = 32 patients); 14 patients (13.3%) had postoperative complications directly related to chest wall surgical resection and/or reconstruction. We experienced no 30-day mortality; 1-year and 2-year mortality was 8.4% and 16.8%, respectively.Biological mesh represents a valuable option in chest wall reconstruction even when surgical sites are infected or at high-risk of infections. This mesh shows low early and late postoperative complication rates and excellent long-term stability.
- Published
- 2022
- Full Text
- View/download PDF